BOYDSense SAS

BOYDSense, an award-winning startup with R&D in France and the U.S., is a pioneer in the development of non-invasive breath analysis solutions for the screening, monitoring, and detection of different biomarkers in exhaled breath. 

It detects the type and concentration of volatile organic compounds (VOCs) in the exhaled breath and multianalytes. 

BOYDSense has developed a unique platform with three unique components:  A miniaturized breath sampling module, a proprietary Sensor array, a proprietary smart algorithm.  

The miniaturized breath sampling module is important to have no leakage, high repeatability, ensure that the measure of VOCs is done at highest concentration part, only the valuable information of the exhaled breath. 

The Sensor array measures VOCs with accuracy and precision. Machine learning and deep learning is used to summarize features.

Smart Algorithm

analyze and calculate glucose concentration. AI is used to find hidden patterns in the database and labelling the data.

1. All this 3 parts are essential to build a unique breath platform for multiple applications. We are targeting a 1bn population with our first device and Apps that we will launch end of 2026.
2. A new wearable or better breathable biomarker, supporting people who like to better manage their weight with a fat burn status and carbohydrate levels.
3. The second product is a medical device providing 3 glucose ranges (below, in or above range) for people with Pre-diabetes or diagnosed type-2 diabetes without Insulin.
4. We have results from 4 clinical trials •3,500+ lab-verified datasets.
5. 99.5% accuracy in clinical safe zones, 94% correctly classified results for Ranges, showing a very good reliability.
6. Our team has years of experience with Volatile organic compounds, therefore knows how to mitigate potential interference testing (food, drinks, smoking, hygiene products).
7. Both products are non invasive, therefore pain-free, affordable and easy accessible.
8. The platform allows us to measure Ketones medical grade and fatty liver disease risk stratification is on of the newt application we will work on. 

We raised already 20m€ and are supported and secured by a trusted board consisting of the European Innovation Council Fund, the Swiss Diabetes Venture Fund,  Jolt Capital, Ambrosia and Bioserenity. 

We are raising up to €20m, whereas €5m will allow us to finalize and launch the Consumer product.